Suboptimal Responses in Chronic Myeloid Leukemia

por Jabbour, Elias, Saglio, Giuseppe, Hughes, Timothy P, Kantarjian, Hagop
Publicado 2012

Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitro

por Blake, Stephen J, Lyons, A Bruce, Hughes, Timothy P
Publicado 2009

ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines

por Eadie, Laura N., Hughes, Timothy P., White, Deborah L.
Publicado 2016

Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia

por Poudel, Govinda, Tolland, Molly G., Hughes, Timothy P., Pagani, Ilaria S.
Publicado 2022

Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers

por Krishnan, Vaidehi, Kim, Dennis Dong Hwan, Hughes, Timothy P., Branford, Susan, Ong, S. Tiong
Publicado 2021

ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells

por Eadie, Laura N., Dang, Phuong, Goyne, Jarrad M., Hughes, Timothy P., White, Deborah L.
Publicado 2018

The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro

por Eadie, Laura N., Saunders, Verity A., Branford, Susan, White, Deborah L., Hughes, Timothy P.
Publicado 2018

The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associated with each resistance mechanism

por Leow, Benjamin C. S., Kok, Chung H., Yeung, David T., Hughes, Timothy P., White, Deborah L., Eadie, Laura N.
Publicado 2023

The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALL

por Tavakoli Shirazi, Paniz, Eadie, Laura N., Heatley, Susan L., Hughes, Timothy P., Yeung, David T., White, Deborah L.
Publicado 2019

Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib

por Kok, Chung H., Saunders, Verity A., Dang, Phuong, Shanmuganathan, Naranie, White, Deborah, Branford, Susan, Yeung, David, Hughes, Timothy P.
Publicado 2023

Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia

por Irani, Yazad D., Kok, Chung H., Clarson, Jade, Shanmuganathan, Naranie, Branford, Susan, Yeung, David T., Ross, David M., Hughes, Timothy P., Yong, Agnes S. M.
Publicado 2023

Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells

por Wang, Jueqiong, Lu, Liu, Kok, Chung H., Saunders, Verity A., Goyne, Jarrad M., Dang, Phuong, Leclercq, Tamara M., Hughes, Timothy P., White, Deborah L.
Publicado 2017

Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression

por McClure, Barbara J., Heatley, Susan L., Kok, Chung H, Sadras, Teresa, An, Jiyuan, Hughes, Timothy P., Lock, Richard B., Yeung, David, Sutton, Rosemary, White, Deborah L
Publicado 2018

Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia

por Hughes, Timothy P., Laneuville, Pierre, Rousselot, Philippe, Snyder, David S., Rea, Delphine, Shah, Neil P., Paar, David, Abruzzese, Elisabetta, Hochhaus, Andreas, Lipton, Jeffrey H., Cortes, Jorge E.
Publicado 2019

Polycomb Factor PHF19 Controls Cell Growth and Differentiation Toward Erythroid Pathway in Chronic Myeloid Leukemia Cells

por García-Montolio, Marc, Ballaré, Cecilia, Blanco, Enrique, Gutiérrez, Arantxa, Aranda, Sergi, Gómez, Antonio, Kok, Chung H., Yeung, David T., Hughes, Timothy P., Vizán, Pedro, Di Croce, Luciano
Publicado 2021

COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study

por Rea, Delphine, Mauro, Michael J., Cortes, Jorge E., Jiang, Qian, Pagnano, Katia B, Ongondi, Matilda, Kok, Chung Hoow, Evans, Nicola, Hughes, Timothy P., Foundation, International CML
Publicado 2020

Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation

por Adnan Awad, Shady, Brück, Oscar, Shanmuganathan, Naranie, Jarvinen, Timo, Lähteenmäki, Hanna, Klievink, Jay, Ibrahim, Hazem, Kytölä, Soili, Koskenvesa, Perttu, Hughes, Timothy P., Branford, Susan, Kankainen, Matti, Mustjoki, Satu
Publicado 2022

BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia

por Pagani, Ilaria S., Dang, Phuong, Kommers, Ivar O., Goyne, Jarrad M., Nicola, Mario, Saunders, Verity A., Braley, Jodi, White, Deborah L., Yeung, David T., Branford, Susan, Hughes, Timothy P., Ross, David M.
Publicado 2018

Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia

por Stein, Andrew M, Martinelli, Giovanni, Hughes, Timothy P, Müller, Martin C, Beppu, Lan, Gottardi, Enrico, Branford, Susan, Soverini, Simona, Woodman, Richard C, Hochhaus, Andreas, Kim, Dong-Wook, Saglio, Giuseppe, Radich, Jerald P
Publicado 2013

COVID-19 in Patients with Chronic Myeloid Leukemia: Poor Outcomes for Patients with Comorbidities, Older Age, Advanced Phase Disease, and Those from Low-Income Countries: An Update...

por Pagnano, Katia B, Kok, Chung Hoow, Mauro, Michael J., Cortes, Jorge E., Evans, Nicola, Jiang, Qian, Milojkovic, Dragana, Moiraghi, Beatriz, Nicolini, Franck E., Ongondi, Matilda, Zackova, Daniela, Rea, Delphine, Hughes, Timothy P.
Publicado 2021